Results 121 to 130 of about 38,526 (184)

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study. [PDF]

Lancet Reg Health Southeast Asia
Sidhu J, Chakraborty A, Das P, Steffen FD, Kundu S, Basu S, Tarafdar B, Dey T, Kar A, Biswas M, Das A, Sivadasan N, Dasgupta P, Ghara N, Bornhauser B, Bourquin JP, Krishnan S, Saha V.   +17 more
europepmc   +1 more source

Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients. [PDF]

Am J Transl Res
Yu L, Ren L, Hou Z, Yang Y, Zhang K.
europepmc   +1 more source

Inconsistency between serum IgG κ and glomerular IgA λ chain types in proliferative glomerulonephritis with monoclonal deposits successfully treated with daratumumab-based therapy. [PDF]

Medicine (Baltimore)
Chen H, Chen D, Zhang G, Cheng M, Jin J, Niu Z, Zhu R, Guo L, Wang J, Bai Y, Xu J, Cheng Z.   +11 more
europepmc   +1 more source

Tripartite motif-containing protein 28 promotes drug resistance to bortezomib in gastric cancer through proteasome activity regulation. [PDF]

Cytojournal
Xin L, Han S, Wang Z, Yuan X, Ye Y, Liu J, Bao X, Ye J.   +7 more
europepmc   +1 more source

Differential molecular mechanisms of bortezomib sensitization to rhTRAIL in non-small cell lung cancer cell lines. [PDF]

Explor Target Antitumor Ther
Kochany P, Stegehuis JH, de Wilt LHAM, Jansen G, de Jong S, Peters GJ, Kruyt FAE.   +6 more
europepmc   +1 more source

A bortezomib resistance-related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma. [PDF]

Discov Oncol
Ding Y, Xiao M, Zhu J, Jiao X, Guo J, Shudao X, Wang J.   +6 more
europepmc   +1 more source

Dreaming of a better future: drug development in myeloma. [PDF]

Blood Adv
Parikh R, Lonial S.
europepmc   +1 more source

Bortezomib overcomes TRAIL resistance in Burkitt's lymphoma by enhancing apoptosis via reactive oxygen species-mediated DR5 upregulation and MAPK pathway activation. [PDF]

Oncol Lett
Chen J, You Y, Zhao W, Zhou Y, Pu S, Bai X, Yang P, Li M.   +7 more
europepmc   +1 more source

The proteostasis network is a therapeutic target in acute myeloid leukemia.

Blood
Lam K, Kim YJ, Tan EL, Ong CM, Liu AZ, Zhou FJ, Sunshine MJ, Chua BA, Vicenzi S, Chen K, Yu H, Ford PW, Zhou JH, Hong Y, Bennett EJ, Crews LA, Ball ED, Signer RAJ.   +17 more
europepmc   +1 more source